Tuesday, July 7, 2026 | TSX: 24,847 ▲ 0.44% | Gold: $3,342 ▼ 0.19% | BTC: $108,240 ▲ 1.82%

Newsletter Advertise About

Live

TSX24,847▲ +0.44%

S&P 5005,612▲ +0.31%

Gold$3,342▼ −0.19%

BTC$108,240▲ 1.82%

WTI$78.40▲ +1.12%

USD/CAD1.3612▼ −0.08%

Silver$33.80▲ +0.62%

Uranium$92.50▲ +2.44%

TSX24,847▲ +0.44%

S&P 5005,612▲ +0.31%

Gold$3,342▼ −0.19%

BTC$108,240▲ 1.82%

WTI$78.40▲ +1.12%

USD/CAD1.3612▼ −0.08%

Silver$33.80▲ +0.62%

Uranium$92.50▲ +2.44%

Biotech

Biotech

Biotech

Lecanemab Approved in Canada for Early Alzheimer’s A Landmark Moment for Neuroscience Investors

Author · July 2, 2026

Biotech

Canada’s Biosimilar Market Reaches $2.4B as Patent Cliffs Accelerate Generic Competition

Author · July 1, 2026

Biotech

Three CSE-Listed Biotechs With Active Phase 2 Trials That Analysts Are Watching

Author ·

Biotech

Health Canada Approves Apobiologix Biosimilar What It Means for Drug Pricing

Author ·

Biotech

Liquid Biopsy Companies Are Racing Into Canada’s $1.2B Early Cancer Detection Market

Author ·

Biotech

Butterfly Network’s Handheld Ultrasound Is Reshaping Point-of-Care Diagnostics

Author · June 30, 2026

Biotech

Health Canada’s Software-as-Medical-Device Framework Is Unlocking a New Asset Class

Author ·

Biotech

FDA-Health Canada Collaboration Is Cutting Drug Review Times by 18 Months

Author ·

Biotech

Pharmacogenomics Is Going Mainstream in Canadian Hospitals And Changing How Drugs Are Prescribed

Author · June 29, 2026

Biotech

Five TSX-V MedTech Companies With Major Commercial Milestones in H2 2026

Author · June 28, 2026